日付 |
時間 |
ソース |
タイトル |
2024/4/10 | 21:05 | GLOBE | MaxCyte to Report First Quarter 2024 Financial Results on.. |
2024/4/10 | 21:05 | UK RNS | MaxCyte, Inc. Notice of Results |
2024/4/03 | 15:00 | UK RNS | MaxCyte, Inc. Total Voting Rights and Block Listing Return |
2024/4/02 | 23:19 | ALNC | TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian.. |
2024/4/02 | 21:05 | UK RNS | MaxCyte, Inc. Signing of Strategic Platform License |
2024/4/02 | 21:05 | GLOBE | MaxCyte Signs Strategic Platform License with Be Biopharma.. |
2024/4/02 | 15:00 | UK RNS | MaxCyte, Inc. Exercise of options and PDMR dealing |
2024/3/20 | 19:16 | UK RNS | MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR.. |
2024/3/20 | 19:05 | UK RNS | MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR.. |
2024/3/13 | 20:54 | ALNC | IN BRIEF: MaxCyte loss widens in 2023 as core revenue.. |
2024/3/13 | 16:05 | UK RNS | MaxCyte, Inc. Filing of form 10-K for FY ended December 31,.. |
2024/3/13 | 16:00 | UK RNS | MaxCyte, Inc. Reports Q4 & FY 2023 Financial Results |
2024/3/13 | 05:05 | UKREG | MaxCyte Reports Fourth Quarter and Full Year 2023 Financial.. |
2024/3/06 | 17:58 | UK RNS | MaxCyte, Inc. TR-1: Notification of major holdings |
2024/3/06 | 05:43 | ALNC | EARNINGS: dotdigital eyes rosy future; Beeks Financial turns.. |
2024/3/05 | 16:00 | UK RNS | MaxCyte, Inc. Preliminary FY Results & 2024 Guidance |
2024/3/05 | 06:05 | UKREG | MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023.. |
2024/3/02 | 02:57 | UK RNS | MaxCyte, Inc. Total Voting Rights |
2024/2/29 | 18:21 | UK RNS | MaxCyte, Inc. Exercise of options and PDMR dealing |
2024/2/26 | 16:00 | UK RNS | MaxCyte, Inc. TR-1: Notification of major holdings |
2024/2/09 | 22:05 | UK RNS | MaxCyte, Inc. Notice of Results |
2024/2/09 | 22:05 | UKREG | MaxCyte to Report Fourth Quarter and Full Year 2023.. |
2024/2/01 | 18:24 | UK RNS | MaxCyte, Inc. Total Voting Rights |
2024/1/31 | 16:00 | UK RNS | MaxCyte, Inc. Director/PDMR Shareholding |
2024/1/30 | 23:29 | UK RNS | MaxCyte, Inc. Holding(s) in Company |
2024/1/30 | 22:58 | ALNC | IN BRIEF: MaxCyte signs licencing deal with cell therapy.. |
2024/1/30 | 22:05 | UK RNS | MaxCyte, Inc. Signing of Strategic Platform License |
2024/1/30 | 22:05 | UKREG | MaxCyte and Wugen Sign Strategic Platform License to.. |
2024/1/30 | 02:56 | ALNC | IN BRIEF: MaxCyte chief scientific officer leaves firm |
2024/1/30 | 01:52 | UK RNS | MaxCyte, Inc. TR-1: Notification of major holdings |
2024/1/29 | 16:00 | UK RNS | MaxCyte, Inc. Filing of Form 8-K |
2024/1/24 | 03:39 | ALNC | TRADING UPDATES: Esken's Southend Airport faces further.. |
2024/1/23 | 22:05 | UKREG | MaxCyte, Inc. Signing of Strategic Platform License |
2024/1/23 | 22:05 | GLOBE | MaxCyte Signs Strategic Platform License with Imugene to.. |
2024/1/09 | 21:18 | ALNC | MaxCyte's strategic platform licences redeem otherwise.. |
2024/1/09 | 16:00 | UKREG | MaxCyte, Inc. Preliminary Unaudited Q4 and FY 2023 Results |
2024/1/09 | 06:05 | GLOBE | MaxCyte Announces Preliminary Unaudited Fourth Quarter and.. |
2024/1/05 | 16:00 | UKREG | MaxCyte, Inc. Grant of Options and PDMR Dealing |
2024/1/03 | 23:04 | ALNC | MaxCyte teams with Singapore-based Lion to support TCR-T.. |
2024/1/03 | 22:05 | GLOBE | MaxCyte and Lion TCR form Partnership to Support Global.. |
2024/1/03 | 22:05 | UKREG | MaxCyte, Inc. Signing of Strategic Platform License |
2024/1/02 | 18:23 | UKREG | MaxCyte, Inc. Total Voting Rights |
2024/1/02 | 16:00 | GLOBE | MaxCyte Confirms Appointment of Maher Masoud as President,.. |
2024/1/02 | 16:00 | UKREG | MaxCyte, Inc. Confirmation of Board change |
2023/12/29 | 16:00 | UKREG | MaxCyte, Inc. Exercise of options and PDMR dealing |
2023/12/13 | 00:56 | ALNC | TRADING UPDATES: Technology Minerals identifies lithium at.. |
2023/12/12 | 16:00 | UKREG | MaxCyte, Inc. CEO Transition and Revenue Guidance Update |
2023/12/12 | 06:05 | GLOBE | MaxCyte Announces CEO Transition and Updates Revenue.. |
2023/12/07 | 18:50 | UKREG | MaxCyte, Inc. Exercise of options and PDMR dealing |
2023/12/04 | 16:00 | UKREG | MaxCyte, Inc. Exercise of options and PDMR dealing |